Liu Mingli, Zhong Ping
Neurology, Yangpu District Shidong Hospital of Shanghai, No. 999 Shiguang Road, Yangpu District, Shanghai, China.
Indian J Microbiol. 2022 Dec;62(4):494-504. doi: 10.1007/s12088-022-01025-w. Epub 2022 May 19.
Growing evidence suggested that the change of composition and proportion of intestinal microbiota may be related to many diseases, such as irritable bowel syndrome, bipolar disorder, Parkinson's disease, as well as Alzheimer's disease. Current literature supports the fact that unbalanced gut microbial composition (gut dysbiosis) is a risk factor for AD. In our review, we briefly sum up the recent progress regarding the correlations between the gut microbiota and AD. Therapeutic interventions capable of modulating the make-up of the gut microflora may exert beneficial effects on AD, preventing or delaying the beginning of AD or counteracting its development. Additionally, well-documented approaches that can positively influence AD may exert their beneficial effects through modifying the gut microbiota. Therefore, other novel interventions which can target on gut microbiota will also be potential therapies for AD. The chances and challenges that AD is confronted with in the research field of microbiomics are also discussed in this review.
越来越多的证据表明，肠道微生物群的组成和比例变化可能与许多疾病有关，如肠易激综合征、双相情感障碍、帕金森病以及阿尔茨海默病。目前的文献支持肠道微生物组成失衡（肠道生态失调）是阿尔茨海默病的一个危险因素这一事实。在我们的综述中，我们简要总结了关于肠道微生物群与阿尔茨海默病之间相关性的最新进展。能够调节肠道微生物群组成的治疗干预措施可能对阿尔茨海默病产生有益影响，预防或延缓阿尔茨海默病的发病或对抗其发展。此外，有充分文献记载的能够对阿尔茨海默病产生积极影响的方法可能通过改变肠道微生物群发挥其有益作用。因此，其他能够针对肠道微生物群的新型干预措施也将是阿尔茨海默病的潜在治疗方法。本综述还讨论了阿尔茨海默病在微生物组学研究领域所面临的机遇和挑战。
